A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
← catalyst calendarNCT06245408 · readout in 64 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
434actual
Sites
194
Countries
Argentina, Australia, Belgium +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-08 | actual | When the study began enrolling |
| Primary completion | 2026-10-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-17 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sjögren's Syndrome (SS)
Interventions
- Drug: Dazodalibep — also filed as VIB 4920, MEDI4920
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in ESSPRI score
measured At Week 48
Change from baseline in Diary for Assessing Sjogren's Patient Reported Index (DASPRI ) score
measured At week 48
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed